| P2093 | author name string | Peter J Koudstaal | |
| | Peter A E Sillevis Smitt | |
| | Theo M Luider | |
| | Lennard J M Dekker | |
| | Christoph Stingl | |
| | Janne M Papma | |
| | Niels D Prins | |
| | Linda Ijsselstijn | |
| | Wim Calame | |
| P2860 | cites work | Role of 90K protein in asthma and TH2-type cytokine expression. | Q54692161 |
| | Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis | Q24562844 |
| | Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 |
| | 90K (Mac-2 BP) and galectins in tumor progression and metastasis | Q28242012 |
| | Complement: a key system for immune surveillance and homeostasis | Q29615484 |
| | Mild cognitive impairment as a diagnostic entity | Q29619568 |
| | Skyline: an open source document editor for creating and analyzing targeted proteomics experiments | Q30080030 |
| | Current concepts in mild cognitive impairment | Q34104314 |
| | Carboxypeptidase N: a pleiotropic regulator of inflammation | Q34285342 |
| | Mild cognitive impairment in older people. | Q35031167 |
| | Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease | Q35114490 |
| | Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance | Q35894767 |
| | Blood-brain barrier: ageing and microvascular disease--systematic review and meta-analysis | Q36942382 |
| | Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. | Q37493113 |
| | Complement in the brain. | Q37872442 |
| | Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. | Q39986427 |
| | Serum clusterin levels are not increased in presymptomatic Alzheimer's disease | Q44090374 |
| | Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease | Q44784618 |
| | Serum levels of pregnancy zone protein are elevated in presymptomatic Alzheimer's disease | Q45892444 |
| | Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis | Q46076651 |
| | Increased plasma concentration of serum amyloid P component in centenarians with impaired cognitive performance | Q47988703 |
| | Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. | Q48105954 |
| | Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine | Q48390779 |
| | CSF markers related to pathogenetic mechanisms in Alzheimer's disease | Q48424300 |
| | Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain. | Q48730153 |
| | Revised criteria for mild cognitive impairment: validation within a longitudinal population study. | Q51930872 |
| | Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease. | Q51981194 |
| | Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. | Q53235144 |
| P433 | issue | 16 | |
| P921 | main subject | mild cognitive impairment | Q1472703 |
| P304 | page(s) | 2526-2533 | |
| P577 | publication date | 2013-07-19 | |
| P1433 | published in | Proteomics | Q15614164 |
| P1476 | title | Serum proteomics in amnestic mild cognitive impairment | |
| P478 | volume | 13 | |